EW (Edwards) רווח נקי למניה ב-12 החודשים האחרונים

Edwards Lifesciences faces regulatory pressure and labor shortages, yet the business remains resilient to economic crises due to its leadership in cardiac surgery. The trend of earnings per share over the last 12 months on the general GURU.Markets platform chart shows that the 1.71 level is the current value. This is supported by a rigorous management strategy focused on key innovations while divesting non-core assets.

The profitability of Edwards Lifesciences (EW) depends directly on the implementation of innovative TAVR heart valves and monitoring systems, which determines the volume of generated cash flow. By analyzing the specific net income over the last 12 months, an investor assesses the earnings per share adjusted for the impact of issuance to determine the real business efficiency and the dynamics of return on equity without waiting for quarterly reports.